検索結果

acturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibiti...

acturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibiti...

Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

Communications with Customers and Provision of Information to Senju Pharmaceutical has a Customer Service Center for directly responding to inquiries from consumers and patients. The role of the Cente...

論文投稿実績 | 研究開発活動 | 千寿製薬株式会社

坂本祐一郎2)　末信敏秀2)　井上幸次3) 1) 愛媛大学医学部眼科学教室　2)千寿製薬株式会社　3)日野病院 あたらしい眼科42(12)：1566～1576 Efficacy and Safety of SJP-0132 in Patients with Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Stu...

发表论文 | 研究与开发 | 千寿制药株式会社

坂本祐一郎2)　末信敏秀2)　井上幸次3) 1) 愛媛大学医学部眼科学教室　2)千寿製薬株式会社　3)日野病院 あたらしい眼科42(12)：1566～1576 Efficacy and Safety of SJP-0132 in Patients with Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Stu...